[go: up one dir, main page]

WO1993025211A1 - Traitement des douleurs cutanees, du prurit et d'inflammations a l'aide de fluorure d'etain en application locale - Google Patents

Traitement des douleurs cutanees, du prurit et d'inflammations a l'aide de fluorure d'etain en application locale Download PDF

Info

Publication number
WO1993025211A1
WO1993025211A1 PCT/US1993/005812 US9305812W WO9325211A1 WO 1993025211 A1 WO1993025211 A1 WO 1993025211A1 US 9305812 W US9305812 W US 9305812W WO 9325211 A1 WO9325211 A1 WO 9325211A1
Authority
WO
WIPO (PCT)
Prior art keywords
itching
stannous fluoride
inflammation
treatment
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1993/005812
Other languages
English (en)
Inventor
William J. Embro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Embro Research Co LLC
Original Assignee
Embro Research Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Embro Research Co LLC filed Critical Embro Research Co LLC
Priority to AU45388/93A priority Critical patent/AU4538893A/en
Publication of WO1993025211A1 publication Critical patent/WO1993025211A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof

Definitions

  • the present invention relates to a treatment for the cutaneous pain, itching and inflammation often associated with allergies, burns, trauma, insect bites and bacterial, viral and fungal infections. More particularly, the invention relates to the topical application of stannous fluoride for the treatment of such symptoms.
  • the present invention meets this object by providing a treatment which includes the topical application of stannous fluoride.
  • a non-toxic amount of stannous fluoride is incorporated into a pharmaceutical carrier, such as a gel, ointment, cream, lotion or the like, and applied at the site of the inflammation, itching or lesion.
  • the stannous fluoride is provided in a concentration ranging from about 0.1 wt. % to about 8 wt. %.
  • the stannous fluoride is applied as a 0.4% SnF2 glycerin-based gel.
  • the frequency of application may range anywhere from one to six times a day or on an as needed basis.
  • the course of therapy typically ranges from one to ten days but may be continued as long as required for complete relief. DETAILED DESCRIPTION OF THE INVENTION
  • a non-aqueous stannous fluoride gel is prepared by solubilizing SnF2 in glycerin at approximately 150°F for four hours.
  • the resulting gel is a stable solution having an indefinite shelf life that is ideal for topical application to the skin and mucusal tissues.
  • stannous fluoride promotes relief from pain, itching and inflammation; however, the mechanism by which the compound effects these results is not clearly understood.
  • tin (Sn ++ ) and fluoride (F”) ions interact together and affect nerve action potentials, histamine release, cellular enzyme systems and vascular systems, all of which can influence the pain, itching and inflammation caused by infection, allergies and trauma.
  • EXAMPLE 1 Two patients exhibiting an allergic reaction to poison ivy were instructed to apply 0.4% SnF2 gel 4 to 6 times a day or on an as needed basis. Relief from pain and itching was obtained almost immediately.
  • EXAMPLE 2 Five patients with burns were instructed to apply 0.4% SnF2 gel 4 to 6 times a day or on an as needed basis. Relief from the pain associated with the bums was obtained almost immediately.
  • EXAMPLE 3 Ten patients having insect bites (7 mosquitoes, 2 bees) received immediate relief from the associated pain, inflammation and itching when 0.4% SnF2 gel was applied. EXAMPLE 4
  • EXAMPLE 5 Fifteen patients infected with herpes zoster virus and 30 patients infected with herpes simplex virus were instructed to apply 0.4% SnF2 gel 4 to 6 times a day. The pain and itching associated with the infections was either eliminated completely or significantly reduced.
  • EXAMPLE 6 Eight patients having acne infections of bacterial origin on the skin obtained relief from the pain associated with the infections when 0.4% SnF2 gel was applied.
  • EXAMPLE 7 Two patients infected with ringworm and eight patients infected with athletes foot were instructed to apply 0.4% SnF2 gel 4 to 6 times a day or on an as needed basis. Relief from the itching and pain associated with the infections was obtained almost immediately.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un traitement des douleurs cutanées, du prurit et d'inflammations associées à des allergies, des brûlures, des traumas, des piqûres d'insectes et des infections bactériennes, virales et fongiques. Selon l'invention, une dose non toxique de fluorure d'étain est incorporée dans un excipient pharmaceutique approprié et administrée localement.
PCT/US1993/005812 1992-06-16 1993-06-16 Traitement des douleurs cutanees, du prurit et d'inflammations a l'aide de fluorure d'etain en application locale Ceased WO1993025211A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU45388/93A AU4538893A (en) 1992-06-16 1993-06-16 Treatment for cutaneous pain, itching and inflammation with topical stannous fluoride

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89798892A 1992-06-16 1992-06-16
US07/897,988 1992-06-16

Publications (1)

Publication Number Publication Date
WO1993025211A1 true WO1993025211A1 (fr) 1993-12-23

Family

ID=25408759

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/005812 Ceased WO1993025211A1 (fr) 1992-06-16 1993-06-16 Traitement des douleurs cutanees, du prurit et d'inflammations a l'aide de fluorure d'etain en application locale

Country Status (3)

Country Link
AU (1) AU4538893A (fr)
WO (1) WO1993025211A1 (fr)
ZA (1) ZA934273B (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658946A (en) * 1996-05-29 1997-08-19 The Procter & Gamble Company Methods for the treatment of herpes virus infections
US5908640A (en) * 1997-07-25 1999-06-01 Embro; William J. Veterinary compositions for treating epidermal irritations
EP0801554A4 (fr) * 1994-12-21 2000-03-29 Cosmederm Technologies Formulations et procedes pour diminuer l'irritation de la peau
US6294186B1 (en) 1997-06-04 2001-09-25 Peter William Beerse Antimicrobial compositions comprising a benzoic acid analog and a metal salt
US6436885B2 (en) 2000-01-20 2002-08-20 The Procter & Gamble Company Antimicrobial cleansing compositions containing 2-pyrrolidone-5-carboxylic acid
US7404967B2 (en) 1994-12-21 2008-07-29 Cosmederm, Inc. Topical product formulations containing strontium for reducing skin irritation
EP4014962A1 (fr) * 2020-12-16 2022-06-22 Novigo GmbH & Co. KG Composition comprenant une substance à action osmotique et utilisation de la composition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563489A (en) * 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
US4639366A (en) * 1984-06-06 1987-01-27 Merck & Co., Inc. Polymers containing pendant acid functionalities and labile backbone bonds
US5013649A (en) * 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5024841A (en) * 1988-06-30 1991-06-18 Collagen Corporation Collagen wound healing matrices and process for their production

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563489A (en) * 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
US4639366A (en) * 1984-06-06 1987-01-27 Merck & Co., Inc. Polymers containing pendant acid functionalities and labile backbone bonds
US5013649A (en) * 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5024841A (en) * 1988-06-30 1991-06-18 Collagen Corporation Collagen wound healing matrices and process for their production

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0801554A4 (fr) * 1994-12-21 2000-03-29 Cosmederm Technologies Formulations et procedes pour diminuer l'irritation de la peau
US8449923B2 (en) 1994-12-21 2013-05-28 Cosmederm Bioscience, Inc. Methods for inhibiting sensory nerves by topically administering strontium-containing compositions to keratinized skin
US8147855B2 (en) 1994-12-21 2012-04-03 Cosmederm Bioscience, Inc. Methods for inhibiting sensory responses in the skin such as pain and itch using topical product formulations containing strontium
US7404967B2 (en) 1994-12-21 2008-07-29 Cosmederm, Inc. Topical product formulations containing strontium for reducing skin irritation
US6455076B1 (en) 1994-12-21 2002-09-24 Gary S. Hahn Formulations and methods for reducing skin irritation
US5747070A (en) * 1996-05-29 1998-05-05 The Procter & Gamble Company Methods for the treatment of herpes virus infections
US5658946A (en) * 1996-05-29 1997-08-19 The Procter & Gamble Company Methods for the treatment of herpes virus infections
US5744167A (en) * 1996-05-29 1998-04-28 The Procter & Gamble Company Methods for the treatment of herpes virus infections
GB2313543A (en) * 1996-05-29 1997-12-03 Procter & Gamble Compositions containing stannous halides and/or stannous carboxylates for the treatment of herpes virus infections
US6294186B1 (en) 1997-06-04 2001-09-25 Peter William Beerse Antimicrobial compositions comprising a benzoic acid analog and a metal salt
US5908640A (en) * 1997-07-25 1999-06-01 Embro; William J. Veterinary compositions for treating epidermal irritations
US6436885B2 (en) 2000-01-20 2002-08-20 The Procter & Gamble Company Antimicrobial cleansing compositions containing 2-pyrrolidone-5-carboxylic acid
EP4014962A1 (fr) * 2020-12-16 2022-06-22 Novigo GmbH & Co. KG Composition comprenant une substance à action osmotique et utilisation de la composition
WO2022129425A1 (fr) * 2020-12-16 2022-06-23 Novigo GmbH & Co. KG Composition contenant une substance osmotique et utilisation de la composition

Also Published As

Publication number Publication date
AU4538893A (en) 1994-01-04
ZA934273B (en) 1994-08-01

Similar Documents

Publication Publication Date Title
EP1085804B1 (fr) Procede et composition pour le traitement d'irritations et d'infections epidermiques
CA1320909C (fr) Composition topique pour le traitement de lesions cutaneo-muqueuses
US4708965A (en) Method of treating herpes virus infections with N,N'-diacetylcystine and derivatives
US6555125B2 (en) Lesion and ulcer medication
US4424232A (en) Treatment of herpes simplex
Niwa Lipid peroxides and superoxide dismutase (SOD) induction in skin inflammatory diseases, and treatment with SOD preparations
US6352711B1 (en) Lesion and ulcer medication
US20040131693A1 (en) Composition with a base of a therapeutically active compound, in particular honey, for the treatment of wounds
EP0988040B1 (fr) Utilisation de glucosamine et de derives de glucosamine pour le soulagement rapide de prurit ou de douleurs localisees
US5420114A (en) Methods for the treatment of skin disorders
KR101099550B1 (ko) 봉독을 유효성분으로 하는 상처 또는 화상 치료용 조성물
WO1993025211A1 (fr) Traitement des douleurs cutanees, du prurit et d'inflammations a l'aide de fluorure d'etain en application locale
US5098716A (en) Method and composition for treating diseases having a viral etiology
US6562326B1 (en) Topical composition for burn healing
US5049580A (en) Treatment of inflamed skin conditions including poison ivy and poison sumac, insect bites and acne
WO1992006700A1 (fr) Preparation topique et procede de suppression d'eruptions cutanees provoquees par le virus de l'herpes simplex
US3751565A (en) Therapeutic compositions
DE69219470D1 (de) Topisches Präparat zur besseren Heilung von Herpesverletzungen
US4466956A (en) Method of therapy for oral herpes simplex
US3764669A (en) Method of making microbiocidal complexes
US5151415A (en) Method of treating a papova-type viral infection
US5977176A (en) Compositions for the treatment of warts and herpes
US5576005A (en) Effectiveness of wart removal by compositions including propolis
US20030092682A1 (en) Use of doxycycline for treatment of certain skin and mouth ailments
US5908640A (en) Veterinary compositions for treating epidermal irritations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR BY CA CZ FI HU JP KP KR KZ LK MG MN MW NO NZ PL RO RU SD SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase
122 Ep: pct application non-entry in european phase